ARVN
ARVINAS, INC.Company Information
- Company Name
- ARVINAS, INC.
- CIK
- CIK0001655759
- Category
- Accelerated filer
- Ticker: Exchange
- ARVN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ARVN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-06
- Last sale
- 2026-06-24
- Shares purchased (TTM)
- 50,000
- Shares sold (TTM)
- 131,956
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 53,494,181
- Shares outstanding
- 64,800,000
- Ownership
- 82.55%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 2.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 94 | 87 | 143 | 102 | 115 | 81 | 101 | 85 | 155 | 88 | 312 | 114 | ||||||
| Restricted Cash Current | - | - | 0 | - | - | - | 0 | 0 | 6 | 6 | 6 | 6 | ||||||
| Marketable Securities Current | 474 | 528 | 543 | 686 | 746 | 873 | 939 | 1,036 | 1,074 | 1,081 | 949 | 885 | ||||||
| Accounts Receivable Net Current | 50 | 2 | 1 | 20 | 1 | 0 | 6 | 7 | 2 | 0 | 0 | 16 | ||||||
| Other Receivables Net Current | 4 | 5 | 5 | 7 | 11 | 8 | 8 | 8 | 10 | 7 | 7 | 5 | ||||||
| Prepaid Expense And Other Assets Current | 30 | 9 | 9 | 12 | 17 | 17 | 14 | 13 | 13 | 8 | 7 | 8 | ||||||
| Assets Current | 652 | 631 | 701 | 826 | 890 | 980 | 1,067 | 1,150 | 1,257 | 1,190 | 1,280 | 1,033 | ||||||
| Property Plant And Equipment Net | 5 | 6 | 5 | 5 | 6 | 7 | 7 | 7 | 10 | 10 | 12 | 13 | ||||||
| Operating Lease Right Of Use Asset | 7 | 8 | 8 | 9 | 9 | 10 | 9 | 1 | 2 | 2 | 3 | 3 | ||||||
| Assets | 675 | 648 | 718 | 844 | 909 | 1,001 | 1,091 | 1,167 | 1,280 | 1,213 | 1,305 | 1,058 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 52 | 62 | 70 | 56 | 53 | 71 | 72 | 76 | 78 | 76 | 92 | 91 | ||||||
| Contract With Customer Liability Current | 0 | 52 | 71 | 88 | 103 | 141 | 156 | 199 | 268 | 163 | 163 | 224 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | ||||||
| Liabilities Current | 83 | 116 | 143 | 145 | 158 | 214 | 230 | 276 | 347 | 241 | 257 | 317 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 138 | 134 | 127 | 134 | 118 | 292 | 305 | 331 | 361 | 386 | 282 | ||||||
| Long Term Debt Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 6 | 6 | 7 | 7 | 8 | 8 | 7 | 0 | 0 | 0 | 1 | 1 | ||||||
| Liabilities | 113 | 261 | 284 | 280 | 300 | 341 | 530 | 581 | 679 | 603 | 645 | 601 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -1,501 | -1,670 | -1,612 | -1,545 | -1,510 | -1,449 | -1,532 | -1,487 | -1,437 | -1,402 | -1,333 | -1,178 | ||||||
| Additional Paid In Capital | 2,155 | 2,149 | 2,137 | 2,128 | 2,118 | 2,107 | 2,092 | 2,068 | 2,041 | 2,016 | 1,996 | 1,644 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 1 | 1 | 1 | 2 | 1 | 4 | -4 | -4 | -3 | -9 | ||||||
| Treasury Stock Value | - | - | - | -20 | - | - | - | - | - | - | - | - | ||||||
| Treasury Stock Common Value | -92 | -92 | -92 | - | - | - | 0 | - | - | - | - | - | ||||||
| Stockholders Equity | 562 | 387 | 434 | 564 | 609 | 660 | 562 | 586 | 600 | 610 | 660 | 457 | ||||||
| Liabilities And Stockholders Equity | 675 | 648 | 718 | 844 | 909 | 1,001 | 1,091 | 1,167 | 1,280 | 1,213 | 1,305 | 1,058 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 75 | 75 | 74 | 73 | 73 | 73 | 69 | 69 | 69 | 68 | 68 | 55 | ||||||
| Shares Outstanding | 65 | 65 | 64 | 71 | 73 | 73 | 69 | 69 | 69 | 68 | 68 | 55 | ||||||
| Treasury Stock Common Shares | 10 | 10 | 10 | 3 | - | - | 0 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialARVINAS, INC. (ARVN) — SEC Financial Statements & Analysis
ARVINAS, INC. (ARVN) is a pharmaceutical preparations company, incorporated in DE. ARVINAS, INC. trades on Nasdaq as: ARVN. ARVINAS, INC. (ARVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, ARVINAS, INC. carries a market cap of $538.49M, a P/E ratio of 57.90x, a P/B ratio of 0.96x, a P/S ratio of 1.70x, an enterprise value of $444.49M, and an EV/EBITDA multiple of -29.24x. On profitability, it posts an operating margin of -5.72%, a net margin of 2.94%, a Return on Equity (ROE) of 1.59%, a Return on Assets (ROA) of 1.17%, and a Return on Invested Capital (ROIC) of -3.71%. Per share, it reports EPS of $0.14, diluted EPS of $0.14, free cash flow per share of $-3.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -15.05% year-over-year, net income growth of -112.81% year-over-year, and EPS growth of -114.43% year-over-year. On the balance sheet, it maintains a current ratio of 7.91x, a quick ratio of 7.54x, working capital of $569.70M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.17, free cash flow of $-208.80M (TTM), and net debt of $-94.00M. Figures sourced from SEC EDGAR.
- Market Cap
- $538.49M
- P/E TTM
- 57.90x
- EPS TTM
- $0.14
- P/B TTM
- 0.96x
- ROE TTM
- 1.59%
- ROA TTM
- 1.17%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-208.80M
- Net Revenue TTM Growth 1Y
- -15.05%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ARVINAS, INC. in?
ARVINAS, INC. (ARVN) operates in the Pharmaceutical Preparations industry.
What exchange does ARVN trade on?
ARVINAS, INC. (ARVN) trades on the Nasdaq.
Where is ARVINAS, INC. incorporated?
ARVINAS, INC. is incorporated in DE.
When was ARVINAS, INC. (ARVN)'s most recent SEC filing?
ARVINAS, INC. (ARVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is ARVN's market cap?
ARVINAS, INC. (ARVN) has a market capitalization of $538.49M as of 2026-06-30.
What is ARVN's P/E ratio?
ARVINAS, INC. (ARVN)'s trailing twelve month P/E ratio is 57.90x as of 2026-06-30.
What is ARVN's EPS (earnings per share)?
ARVINAS, INC. (ARVN)'s trailing twelve month EPS is $0.14 as of 2026-06-30.
What is ARVN's ROE (return on equity)?
ARVINAS, INC. (ARVN)'s trailing twelve month Return on Equity (ROE) is 1.59% as of 2026-06-30.
What is ARVN's ROA (return on assets)?
ARVINAS, INC. (ARVN)'s trailing twelve month Return on Assets (ROA) is 1.17% as of 2026-06-30.
What is ARVN's ROIC (return on invested capital)?
ARVINAS, INC. (ARVN)'s trailing twelve month Return on Invested Capital (ROIC) is -3.71% as of 2026-06-30.
What is ARVN's EV/EBITDA?
ARVINAS, INC. (ARVN)'s trailing twelve month EV/EBITDA is -29.24x as of 2026-06-30.